Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD-044 in Moderate to Severe Atopic Dermatitis
2024-511615-16-00Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vibozilimod in atopic dermatitis (AD) (5 arms), sponsored by Sun Pharma. Primary endpoint: EASI-75 response at Week 16. Started Oct 2024; status: completed.
02
Drugs
vibozilimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-511615-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511615-16-00.